Caris Life Sciences, Inc. (NASDAQ:CAI) Receives Average Rating of “Hold” from Brokerages

Caris Life Sciences, Inc. (NASDAQ:CAI) has been given a consensus recommendation of “Hold” by the five research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $30.60.

A number of analysts have commented on the company. Evercore set a $38.00 target price on Caris Life Sciences in a report on Monday, January 5th. Wall Street Zen raised Caris Life Sciences from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Weiss Ratings reissued a “sell (d)” rating on shares of Caris Life Sciences in a report on Monday, December 29th. The Goldman Sachs Group assumed coverage on Caris Life Sciences in a report on Wednesday, April 1st. They issued a “buy” rating and a $27.00 target price for the company. Finally, BTIG Research reduced their target price on Caris Life Sciences from $45.00 to $38.00 and set a “buy” rating for the company in a report on Friday, February 27th.

Institutional Trading of Caris Life Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. Global Retirement Partners LLC grew its holdings in shares of Caris Life Sciences by 99,900.0% in the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after acquiring an additional 999 shares during the period. Olistico Wealth LLC bought a new stake in shares of Caris Life Sciences in the fourth quarter worth $31,000. MetLife Investment Management LLC grew its holdings in shares of Caris Life Sciences by 84.0% in the fourth quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock worth $45,000 after acquiring an additional 755 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in shares of Caris Life Sciences in the fourth quarter worth $67,000. Finally, Federated Hermes Inc. bought a new stake in shares of Caris Life Sciences in the fourth quarter worth $81,000.

Caris Life Sciences Stock Down 1.4%

CAI stock opened at $18.75 on Wednesday. Caris Life Sciences has a twelve month low of $16.28 and a twelve month high of $42.50. The company has a current ratio of 7.85, a quick ratio of 7.35 and a debt-to-equity ratio of 0.66. The company has a market cap of $5.30 billion and a price-to-earnings ratio of -104.17. The company’s 50 day moving average is $19.91.

Caris Life Sciences (NASDAQ:CAI) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.27. The company had revenue of $292.89 million for the quarter, compared to the consensus estimate of $281.00 million. During the same period last year, the business earned ($1.73) EPS. The firm’s quarterly revenue was up 125.4% on a year-over-year basis.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.